Trevor Martin
Family Medicine · Washington, IANPI 1770725202
Payments from drug & device makers
Across 120 payments — averaging $12.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$411
- AstraZeneca$198
- Pfizer$175
- Amgen$166
- Johnson & Johnson$116
- AbbVie$81
- plus $342 from 13 others
What the payments were for
- Food & beverage$1,483100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 29 | $411 |
| AstraZeneca | 9 | $198 |
| Pfizer | 26 | $175 |
| Amgen | 12 | $166 |
| Johnson & Johnson | 12 | $116 |
| AbbVie(2 entities) | 6 | $81 |
| Novartis | 4 | $75 |
| GSK | 4 | $46 |
| Novo Nordisk | 3 | $39 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $27 |
| Astellas Pharma US Inc | 2 | $26 |
| Teva Pharmaceuticals USA, Inc. | 2 | $25 |
| Merck | 1 | $16 |
| Alfasigma USA, Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Boehringer Ingelheim | 1 | $12 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $11 |
How this compares
$1,488 in reported general payments places this provider in the 85th percentile of 1,357 family medicine providers in Iowa.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 50 | $69,855 |
| EliquisApixaban | 87 | $69,376 |
| TrulicityDulaglutide | 30 | $29,946 |
| XareltoRivaroxaban | 15 | $24,251 |
| OzempicSemaglutide | 14 | $15,693 |
| FarxigaDapagliflozin Propanediol | 21 | $15,478 |
| MyrbetriqMirabegron | 12 | $12,670 |
| FiaspInsulin Aspart (Niacinamide) | 14 | $11,052 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $9,375 |
| Emgality PenGalcanezumab-Gnlm | 12 | $8,231 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $8,019 |
| Varenicline Tartrate | 19 | $3,414 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 113 | $2,609 |
| Levothyroxine Sodium | 354 | $2,579 |
| Metoprolol Succinate | 155 | $2,534 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $12 | $69,85550 claims |
| PfizerEliquis | $175 | $69,37687 claims |
| Novo NordiskOzempic, Fiasp | $39 | $26,74528 claims |
| Johnson & JohnsonXarelto | $116 | $24,25115 claims |
| AstraZenecaFarxiga | $198 | $15,47821 claims |
| Astellas Pharma US IncMyrbetriq | $26 | $12,67012 claims |
| AbbVieSynthroid | $81 | $1,53045 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,357 family medicine providers in Iowa.
Other family medicine in Washington
- Nicholas GoetschWaterloo$4.1M
- James PoockWaterloo$1.5M
- Jennifer KayCouncil Bluffs$613K
- Nicholas BechtoldSioux City$584K
- Kirk PetersonHuxley$576K
- Stephen HarrisonClinton$249K
- Sharon SteenBelle Plaine$241K
- Carlos Alarcon SchroderJohnston$237K
- Thomas RossDes Moines$170K
- Yogesh ShahDes Moines$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.